FGEN
$41.62
Fibrogen Inc CS
($1.39)
(3.23%)
FGEN
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.89)
Revenue:  $47.84 Mil
Thursday
Nov 5
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, August 06, 2020

What do you expect when FGEN reports earnings?
Beat
Meet
Miss

Where is FGEN's stock price going from here?
Up
Flat
Down
Stock chart of FGEN
Analysts
Summary of analysts' recommendations for FGEN
Score
Grade
Pivots
Resistance
$44.21
$43.64
$42.63

$42.06

Support
$41.05
$40.48
$39.47
Tweet
Growth
Description
FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.
Peers
InterCeptBioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsZoetisJohnson & JohnsonMerck & Co.Ultragenyx PharmaceuticalBristol-Myers SquibbCatalent